Page last updated: 2024-11-05

troglitazone and Hyperglycemia, Postprandial

troglitazone has been researched along with Hyperglycemia, Postprandial in 16 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Hyperglycemia, Postprandial: Abnormally high BLOOD GLUCOSE level after a meal.

Research Excerpts

ExcerptRelevanceReference
"In conclusion, PPARγ agonist, troglitazone improved glucose transport SGLT2 dysfunction and subsequent glucagon dysregulation in alpha cell under hyperglycemia."7.85The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia. ( Jung, HS; Kim, M; Kim, TK; Kim, TN; Kwon, MJ; Lee, EJ; Lee, SH; Park, JH; Rhee, BD; Shin, HM, 2017)
"Metformin-treated rats gained significantly less weight."5.29Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. ( Burant, CF; Polonsky, KS; Pugh, W; Sreenan, S; Sturis, J, 1996)
"In conclusion, PPARγ agonist, troglitazone improved glucose transport SGLT2 dysfunction and subsequent glucagon dysregulation in alpha cell under hyperglycemia."3.85The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia. ( Jung, HS; Kim, M; Kim, TK; Kim, TN; Kwon, MJ; Lee, EJ; Lee, SH; Park, JH; Rhee, BD; Shin, HM, 2017)
"To determine the relationship between hypoglycemic activity and body weight gain induced by insulin sensitizers, we compared the effects of thiazolidinedione analogs (troglitazone and pioglitazone) and the oxadiazolidinedione analog (Z)-1,4-bis4[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phen oxy¿but-2-ene (YM440) in diabetic db/db mice."3.70The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. ( Hirayama, R; Kurosaki, E; Nakano, R; Shibasaki, M; Shikama, H; Shimaya, A, 2000)
"Diabetes mellitus is associated with alterations in a number of key metabolic pathways."2.40Drug administration in patients with diabetes mellitus. Safety considerations. ( Cooper, ME; Gilbert, RE; Krum, H, 1998)
"Troglitazone (TGZ) treatment, beginning at 6 weeks of age, prevented the hyperglycemia, the hyperlipidemia, and the increase in 11beta-HSD-1."1.32Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone. ( Agarwal, AK; Duplomb, L; Lee, Y; Park, BH; Takaishi, K; Unger, RH; Wang, MY, 2004)
"Treatment with troglitazone resulted in a significant, specific decrease in type I collagen along with a slight decrease in laminin production in both medium conditions."1.31Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. ( Johnson, JH; McCarthy, KJ; Routh, RE, 2002)
"Metformin-treated rats gained significantly less weight."1.29Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. ( Burant, CF; Polonsky, KS; Pugh, W; Sreenan, S; Sturis, J, 1996)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (37.50)18.2507
2000's8 (50.00)29.6817
2010's2 (12.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berger, J1
Bailey, P1
Biswas, C1
Cullinan, CA1
Doebber, TW1
Hayes, NS1
Saperstein, R1
Smith, RG1
Leibowitz, MD1
Kim, M1
Lee, EJ1
Shin, HM1
Jung, HS1
Kim, TK1
Kim, TN1
Kwon, MJ1
Lee, SH1
Rhee, BD1
Park, JH1
Liang, YJ1
Jian, JH1
Chen, CY1
Hsu, CY1
Shih, CY1
Leu, JG1
Wu, L1
Davies, GF1
Roesler, WJ1
Juurlink, BH1
Duplomb, L1
Lee, Y1
Wang, MY1
Park, BH1
Takaishi, K1
Agarwal, AK1
Unger, RH1
Sreenan, S1
Sturis, J1
Pugh, W1
Burant, CF1
Polonsky, KS1
Okuno, A1
Tamemoto, H1
Tobe, K1
Ueki, K1
Mori, Y1
Iwamoto, K1
Umesono, K1
Akanuma, Y1
Fujiwara, T2
Horikoshi, H2
Yazaki, Y1
Kadowaki, T2
Gilbert, RE1
Cooper, ME1
Krum, H1
Skyler, JS1
Shimaya, A1
Kurosaki, E1
Nakano, R1
Hirayama, R1
Shibasaki, M1
Shikama, H1
Murao, S1
Hirata, K1
Ishida, T1
Takahara, J1
Stiefelhagen, P1
McCarthy, KJ2
Routh, RE2
Shaw, W1
Walsh, K1
Welbourne, TC1
Johnson, JH2
Wada, M1
Fukuda, K1
Fukami, M1
Yoshioka, S1
Yoshioka, T1

Reviews

2 reviews available for troglitazone and Hyperglycemia, Postprandial

ArticleYear
Drug administration in patients with diabetes mellitus. Safety considerations.
    Drug safety, 1998, Volume: 18, Issue:6

    Topics: Acarbose; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Ag

1998
[Hypoglycemic agents to improve insulin resistance].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:2

    Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Anim

2000

Other Studies

14 other studies available for troglitazone and Hyperglycemia, Postprandial

ArticleYear
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
    Endocrinology, 1996, Volume: 137, Issue:10

    Topics: Animals; Blood Glucose; COS Cells; Cricetinae; Diabetes Mellitus; Hyperglycemia; Hypertriglyceridemi

1996
The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia.
    Journal of endocrinological investigation, 2017, Volume: 40, Issue:10

    Topics: Animals; Cells, Cultured; Chromans; Gene Expression Regulation; Glucagon; Glucagon-Secreting Cells;

2017
L-165,041, troglitazone and their combination treatment to attenuate high glucose-induced receptor for advanced glycation end products (RAGE) expression.
    European journal of pharmacology, 2013, Sep-05, Volume: 715, Issue:1-3

    Topics: Apoptosis; Chromans; Cytokines; Drug Interactions; Gene Expression Regulation; Glucose; HEK293 Cells

2013
Regulation of the glyoxalase pathway in human brain microvascular endothelium: effects of troglitazone and tertiary butylhydroperoxide.
    Endothelium : journal of endothelial cell research, 2002, Volume: 9, Issue:4

    Topics: Animals; Brain; Cells, Cultured; Cerebrovascular Circulation; Chromans; Dose-Response Relationship,

2002
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
    Biochemical and biophysical research communications, 2004, Jan-16, Volume: 313, Issue:3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Animals, Genetically Modified; Blotting, Weste

2004
Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone.
    The American journal of physiology, 1996, Volume: 271, Issue:4 Pt 1

    Topics: Age Factors; Animals; Body Weight; Chromans; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified;

1996
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
    The Journal of clinical investigation, 1998, Mar-15, Volume: 101, Issue:6

    Topics: Adipocytes; Adipose Tissue; Animals; Apoptosis; Blood Glucose; Blotting, Northern; Body Weight; Chro

1998
Targeted glycemic control in type 2 diabetes.
    The Journal of the Florida Medical Association, 1998, Volume: 85, Issue:2

    Topics: Aged; Algorithms; Anti-Obesity Agents; Biguanides; Blood Glucose; Blood Glucose Self-Monitoring; Chr

1998
The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
    Metabolism: clinical and experimental, 2000, Volume: 49, Issue:3

    Topics: 3T3 Cells; Adipose Tissue; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Mellitus

2000
Troglitazone in progesterone derivative-induced impairment of glucose tolerance.
    Internal medicine (Tokyo, Japan), 2000, Volume: 39, Issue:4

    Topics: Aged; Antineoplastic Agents, Hormonal; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; G

2000
[New development in diabetes therapy. 35th Annual Meeting of the German Diabetes Society, Munich, May 5-June 3, 2000].
    Der Internist, 2000, Volume: 41, Issue:9

    Topics: Chromans; Diabetes Mellitus, Type 2; Germany; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; P

2000
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
    Kidney international, 2000, Volume: 58, Issue:6

    Topics: Animals; Basement Membrane; Body Weight; Chondroitin Sulfate Proteoglycans; Chromans; Diabetes Melli

2000
Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.
    Kidney international, 2002, Volume: 61, Issue:4

    Topics: Animals; Cells, Cultured; Chromans; Clofibrate; Collagen Type I; Extracellular Matrix Proteins; Glom

2002
Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice.
    Metabolism: clinical and experimental, 1991, Volume: 40, Issue:11

    Topics: Administration, Oral; Animals; Blood Glucose; Chromans; Diabetes Mellitus; Glucagon; Hyperglycemia;

1991